Tenax Therapeutics, Inc. — Form 10-Q Summary
Reporting period: The filing covers the three months ended July 31, 2015, Tenax’s first quarter of fiscal 2016—not 2014 Q1 as indicated in the request metadata. All financial statements are unaudited.
Business context
Tenax is a development-stage specialty pharmaceutical company focused on critical-care therapies. Its lead program is levosimendan, being studied for low cardiac output syndrome (LCOS) in cardiac surgery patients. The company reported no revenue for the quarter. It had discontinued development of Oxycyte, its PFC program, and was evaluating strategic alternatives for it.
Financial results and liquidity
| Metric | Quarter ended July 31, 2015 | Comparable 2014 quarter |
|---|---|---|
| Revenue | None reported | None reported |
| Operating expenses / operating loss | $3.11 million | $2.42 million |
| Net loss | $3.03 million | $2.17 million |
| Net loss per share, basic and diluted | $0.11 | $0.08 |
| Net cash used in operations | $3.84 million | $1.98 million |
- Research and development expense was $1.75 million, up from $0.97 million, primarily reflecting higher levosimendan Phase III trial costs. General and administrative expense declined to $1.37 million from $1.45 million.
- Cash and cash equivalents were $3.65 million at July 31; marketable securities totaled $40.22 million. Combined cash and securities were approximately $43.9 million, versus approximately $48.1 million at April 30, 2015.
- Working capital was $18.35 million, compared with $12.99 million at April 30. Total assets were $78.59 million and stockholders’ equity was $67.37 million.
- Total liabilities were $11.22 million, including $48,376 of current notes payable, a $606,118 warrant liability, and a $7.96 million deferred tax liability. The filing reports no material debt balance beyond the small current notes-payable amount.
- Net loss increased mainly as operating expenses rose and other income fell; the prior-year period included a $274,196 gain from a change in warrant fair value, compared with a $33,673 loss this quarter. Interest expense fell to $1,103 from $46,260 after prior convertible notes matured.
- With no revenue, a meaningful operating margin comparison is not available. Comprehensive loss was $3.10 million, including a $65,874 unrealized loss on marketable securities.
Material changes, outlook, and risks
- As of September 8, 2015, 61 of 70 planned sites were activated and 173 of 760 planned patients enrolled in the Phase III Levo-CTS trial. Tenax expected enrollment to continue through mid-2016. The filing also reported 420 of 516 planned patients enrolled in the Phase II-B LeoPARDS sepsis trial.
- Management estimated existing resources would fund operations through calendar 2017, assuming no acceleration of other development opportunities or unexpected costs. It expects continued losses for at least several years and says additional capital will likely be needed for development and potential commercialization. Financing may be unavailable or require dilution, debt covenants, or surrender of product rights.
- The levosimendan license provides Orion with contingent regulatory milestone payments of up to $3 million, commercialization milestones of up to $13 million, and royalties on sales. No development milestones had been met by July 31, 2015, and no related contingent liability was recorded.
- Levosimendan’s Phase III progress, enrollment, trial outcomes, regulatory approval, manufacturing arrangements, and commercialization funding are significant uncertainties. Management cautioned that trial costs and timelines may vary and that available resources could be consumed faster than expected.
- Oxycyte development had been suspended; Tenax said it did not anticipate significant further trial close-out costs. No goodwill impairment was recorded in the quarter. The filing reported no legal proceedings and no material change in risk factors from the 2015 annual report.
- Management stated disclosure controls were effective as of July 31, 2015, with no significant quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the actual reporting period: the filing is for the quarter ended July 31, 2015 (fiscal Q1 2016).
- Track Levo-CTS and LeoPARDS enrollment, trial completion timing, and any clinical or regulatory updates.
- Assess the cash runway against quarterly operating cash use and the assumptions behind management’s estimate through calendar 2017.
- Review future financing needs and the potential dilution or other conditions of equity, debt, or licensing transactions.
- Monitor levosimendan license milestones, royalties, supply dependence on Orion, and the potential commercialization costs.